Pidilite’s consolidated net profit up by more than 30% in June quarter

Pidilite Industries saw profits rise over thirty percent year-on-year. Revenue from operations increased by more than twenty-one percent during the quarter. Earnings before interest, tax, depreciation, and amortisation also jumped significantly. Sales volume grew by more than eleven percent, aiding the company’s performance. The company implemented price hikes across categories to manage rising input costs.

IPA seeks to regularise ‘legacy’ drugs

The Indian Pharmaceutical Alliance seeks to regularize many drugs. These drugs have been marketed for years without central approval. Examples include sodium valproate and carbamazepine tablets. Regulatory gaps have persisted for over a decade. This situation requires urgent attention from drug authorities.

Japan’s Takeda bets on dengue vax to reshape India playbook

Takeda Pharmaceutical’s new dengue vaccine Qdenga received approval in India. The vaccine is expected to launch commercially in early 2027. It will initially be available through the private market for individuals. Takeda plans to pursue government procurement and National Immunisation Programme inclusion. This move significantly broadens Takeda’s public health focus in India.